HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Longchuan Bai Selected Research

SM 164

3/2012LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling.
5/2011Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment.
4/2011Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases.
11/2008SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Longchuan Bai Research Topics

Disease

23Neoplasms (Cancer)
01/2022 - 10/2008
6Leukemia
08/2018 - 10/2014
5Breast Neoplasms (Breast Cancer)
01/2018 - 05/2011
4Colonic Neoplasms (Colon Cancer)
10/2014 - 09/2006
4Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2014 - 05/2012
2Triple Negative Breast Neoplasms
02/2022 - 01/2017
2Metaplasia
01/2013 - 11/2007
2Stomach Neoplasms (Stomach Cancer)
01/2013 - 11/2007
1Colorectal Neoplasms (Colorectal Cancer)
01/2022
1Glioblastoma (Glioblastoma Multiforme)
01/2021
1Hemolysis
12/2016
1Macular Degeneration (Age-Related Maculopathy)
12/2016
1Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria)
12/2016
1Prostatic Neoplasms (Prostate Cancer)
10/2014
1Osteosarcoma (Osteogenic Sarcoma)
10/2014
1B-Cell Lymphoma (Lymphoma, B Cell)
01/2014
1Inflammation (Inflammations)
01/2013
1Helicobacter Infections
01/2013
1Ovarian Neoplasms (Ovarian Cancer)
03/2012
1Head and Neck Neoplasms (Head and Neck Cancer)
04/2011
1Squamous Cell Carcinoma of Head and Neck
04/2011
1Atrophy
11/2007
1Ataxia Telangiectasia (Louis Bar Syndrome)
09/2006
1Gastrointestinal Neoplasms (Gastrointestinal Cancer)
01/2002

Drug/Important Bio-Agent (IBA)

15Proteins (Proteins, Gene)FDA Link
08/2018 - 01/2002
4Inhibitor of Apoptosis ProteinsIBA
01/2014 - 11/2008
4SM 164IBA
03/2012 - 11/2008
3STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
06/2021 - 11/2019
2Pharmaceutical PreparationsIBA
01/2018 - 03/2012
2indoleIBA
01/2018 - 11/2017
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2008 - 10/2008
2Histone Deacetylase InhibitorsIBA
12/2007 - 09/2006
1apcinIBA
02/2022
1ChromatinIBA
01/2021
1Anaplastic Lymphoma KinaseIBA
11/2020
1Transcription Factors (Transcription Factor)IBA
12/2019
1Proteolysis Targeting ChimeraIBA
08/2018
1snake venom protein C activatorIBA
08/2018
1pyrazoleIBA
01/2018
1quinolineIBA
11/2017
1Complement Factor D (Factor D)IBA
12/2016
1Complement System Proteins (Complement)IBA
12/2016
1compound 18IBA
06/2015
1SAR405838IBA
10/2014
1Oncogene Proteins (Oncogene Protein)IBA
10/2014
1BM-1197IBA
01/2014
1Interleukin-6 (Interleukin 6)IBA
01/2013
1LigandsIBA
01/2013
1compound 30IBA
10/2012
1BM-957IBA
10/2012
1compound 21IBA
05/2012
1CrizotinibIBA
03/2012
1Tyrosine Kinase InhibitorsIBA
03/2012
1Membrane Proteins (Integral Membrane Proteins)IBA
03/2012
1GSK 1363089IBA
03/2012
1tyrosine receptor (receptor, tyrosine)IBA
03/2012
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
03/2012
1Phosphotransferases (Kinase)IBA
03/2012
1Radiation-Sensitizing AgentsIBA
04/2011
1CaspasesIBA
04/2011
1NF-kappa B (NF-kB)IBA
10/2008
1Antineoplastic Agents (Antineoplastics)IBA
10/2008
1Caspase 3 (Caspase-3)IBA
10/2008
1Glutamic Acid (Glutamate)FDA Link
12/2007
1Aspartic Acid (Aspartate)FDA Link
12/2007
1Matrix Metalloproteinase 13IBA
12/2007
1Pepsin A (Pepsin)IBA
11/2007
1GastrinsIBA
11/2007
1Peptides (Polypeptides)IBA
11/2007
1Cyclin-Dependent Kinase Inhibitor p21IBA
09/2006

Therapy/Procedure

8Therapeutics
01/2022 - 12/2012
1Oral Administration
11/2020